Recent Updates
Recently added Catalysts

NIRFLI with ICG

Phase 1

Head and Neck Neoplasms | Small molecule | Oncology |Tactile Systems Technology, Inc.|Last Updated: Apr 9, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment11
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02946021Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related LymphedemaPHASE1 COMPLETED 11Oct 1, 2016Feb 1, 2018Apr 9, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Lymph Movement Measured by ICG Lymphography.
Single Treatment, 2 Weeks of Treatment

Demonstrate the ability of the Flexitouch system to move lymph/enhance lymphatic uptake (indicated by increased functionality of vessels and/or changes in area of dermal backflow) as measured by Indocyanine Green (ICG) lymphography.

Secondary Endpoints
Dermal Backflow Measured by ICG Lymphography.
Single Treatment, 2 Weeks of Treatment
Symptom Alleviation Measured by Survey Response.
Single Treatment, 2 Weeks of Treatment
Ease of Use Measured by Survey Response.
Single Treatment, 2 Weeks of Treatment
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Pneumatic Compression-1 session per dayEXPERIMENTALHead and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
Pneumatic Compression-2 sessions per dayEXPERIMENTALHead and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
Interventions
NameTypeDescription
Head and neck garments for pneumatic compression deviceDEVICEPneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
NIRFLI with ICGDRUGNear-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Participants must be 18 years of age or older * Participants must be diagnosed with Lymphedema of the Head and/or Neck * Participants must be diagnosed with squamous cell carcinoma of the oral cavity, oropharynx or larynx and underwent surgery and radiation as part of their st...

Countries:United States
Unlock Eligibility Criteria